Category Archives: Transhuman News

3 Part DNA of Miracles 30 min
1)My short book which TEACHES HOW TO MAKE IT THROUGH A FINANCIAL AND EMOTIONAL CATASTROPHE. I am getting back double after losing EVERYTHING AND SO I TEACH Y...

By: DNAOFMIRACLES

See the original post:
3 Part DNA of Miracles 30 min - Video

(PRWEB) July 07, 2013

DNA Services of America is very pleased to announce that they are launching a new website focusing on mobile users. DNA Services of America is a company that specializes in DNA paternity testing and DNA ancestry testing. They are distinct in the DNA services industry as they were the first DNA company to successfully launch franchise opportunities and helped paved the way by offering DNA testing services within communities to better serve clients across the United States.

The new website will feature a cleaner design and easier to navigate menus. DNA Services of America has rolled their proprietary software into the new website to help bring both labs and clients together seamlessly. The new website will have all the functionality of the old but with a much needed updated look and feel. As always test results will be available online, when applicable. Access to tests and test information is open to all clients, past and present.

DNA Services of America specializes in all forms of DNA testing. Perhaps the most common of these tests is DNA paternity testing. DNA paternity testing is important in that it helps establish legal responsibility for children. DNA paternity testing is often court ordered. DNA Services of America is also used extensively for police forensic work, helping to establish important DNA based evidence. Forensic DNA testing is important for many smaller communities that do not have access to expensive labs and state owned and operated DNA testing facilities. Ancestry testing is also an important aspect of DNA Services of America. As genealogy has grown, so too has the demand to trace accurate DNA relationships. Ancestral DNA helps establish what parts of the world, what ethnicities, and even what families from which people have descended. Ancestral DNA services are a core competency of DNA Services of America.

DNA Services of America has, since its founding, grown greatly. DNA Services of America created and licensed software, DNA DataLink, which brings their entire franchise network together, streamlining information and results to guarantee accuracy, expedient responses and provide secure, online accessibility. DNA Services of America has since expanded to every state in the US and continues to look for new opportunities throughout the world.

Read the original:
DNA Services of America Launches New Website

DNA tests on extremely rare plants discovered in inland Hawkes Bay offer some hope that the species may yet be saved from extinction. Until recently, just 110 Kakabeak plants (Clianthus maximus, or ngutukk in te reo) were known to exist in the wild but the tests suggest there is greater potential than previously thought for the species to re-establish itself.

Results revealed slight genetic differences between plants discovered in Te Urewera National Park and nearby native forests, suggesting that the population there has crashed to low numbers only relatively recently.

Imported fauna have impacted wild populations of Kakabeak severely and the species now holds New Zealands highest possible threatened plant ranking: Nationally Critical. Although grown widely in gardens, domestic Kakabeak have limited genetic variation and therefore little genetic value.

Testing was conducted by Dr Gary Houliston, a plant geneticist at Landcare Research, on clippings taken by the Forest Lifeforce Restoration (FLR) Trust from six plants discovered on the Waiau Bluffs in Te Urewera National Park and in nearby native forests over the past two years. Their DNA profiles were compared with the genetic make-up of all wild Kakabeak tested to date, with the results revealing slight genetic differences to others tested in Hawke's Bay.

"The genetic diversity of any plant population is a good indicator of that populations strength," said FLR Trust forest manager Pete Shaw. "The fact that these plants were out there highlights the value of continued field searching."

Dr Houliston said the plants discovered by the Trust were a valuable find for restoration purposes.

One of the genetically diverse plants, Rachels Plant, was discovered by Shaw while Trust patron Rachel Hunter was visiting its property in the Maungataniwha Native Forest. This plant has subsequently produced a lot of seed, some of which has been used in the Trusts Kakabeak propagation effort.

"Potentially, this will make for a much more robust lot of plants in our Kakabeak orchards," Shaw said. "With any luck these plants will themselves produce good crops of robust and genetically diverse seed, which we can use to re-establish a viable population of Kakabeak in the wild."

The FLR Trust has already established three Kakabeak seed orchards in protected enclosures at its property in the Maungataniwha Native Forest. Staff are in the process of perfecting a groundbreaking technique to propagate the plants by blasting seeds from a shotgun into likely nursery sites in the wild. Staffer Barry Crene developed the technique using re-loaded shotgun shells packed with regular shotgun pellets, a pulp medium and Kakabeak seed. The shells were then discharged into soil from a range of 20 metres, about the distance a helicopter might have to hover from likely nursery sites in the wild.

As with the Waiau Bluffs, such sites are frequently patches of topsoil on bluffs or cliff faces that are as inaccessible to humans as they are to browsers. Helicopters are often the only way to reach them.

View original post here:
DNA tests raise hope for elusive native plant

BLUE BELL, Pa., July 8, 2013 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that in a preclinical study of its influenza DNA vaccine against the virulent, newly emergent H7N9 flu virus, 100% of the vaccinated animals were protected against sickness and death when they were challenged with a lethal dose of H7N9 virus. The results from a study in mice demonstrated that Inovio's vaccine generated not only hemagglutination inhibition (HAI)-based protection against the H7N9 virus but also strong T-cell responses. Inovio's DNA vaccine created cellular immune responses that could reduce the severity of the infection in a person that acquires the virus and limit the spread of the virus in a pandemic setting. Detailed study results will be presented at an invited plenary session at the TEPIK/APACI International Influenza Symposium being held in Seoul, South Korea, on July 12, 2013.

Inovio researchers constructed a consensus DNA vaccine targeting the HA influenza antigen based on sequences collected from several infected H7N9 patients to create a vaccine that is broadly protective against all H7N9 strains. Inovio's vaccine was administered in mice using its proprietary electroporation-based delivery technology twice, 3 weeks apart; the mice were then exposed to a lethal dose of A/Anhui/1/13 strain of H7N9 virus 4 weeks after the second vaccination. The challenge studies were conducted by Inovio's collaborators at Canada's National Microbiology Laboratory in Winnipeg. Results demonstrated that 100% of the vaccinated animals (n=10) remained healthy without any weight loss (a key indicator of health) and survived while all unvaccinated mice in the control group (n=10) had significant morbidity, including up to 30% weight loss, and died within 8 days of challenge.

This study showed for the first time that an H7N9 flu vaccine can protect against this newly emergent influenza subtype, with the added novelty that Inovio's newly created universal "construct" for this subtype was not matched to the virus strain, suggesting the potential to provide protection against other mutated strains that would be expected to emerge within the H7N9 family of influenza. These results also show the speed at which Inovio can construct and test a DNA vaccine against a new virus or new subtype of a virus.

Dr. J. Joseph Kim, Inovio's President and CEO, said, "We need truly preemptive, broad protection against multiple known and new strains within existing families of viruses. Furthermore, history has shown that new viruses and virus subtypes do periodically emerge H7N9 being just one recent example and speed in creating a new vaccine will be of the essence in pandemic situations. Inovio is proving its abilities on both counts. This new preclinical data further validates the power of Inovio's DNA vaccines to induce antigen-specific antibody and T-cell responses, which we have also demonstrated across other medical conditions such as pre-cancerous lesions and HIV."

Inovio previously reported that this newly developed H7N9 influenza DNA vaccine generated greater than 1:40 hemagglutination inhibition (HAI) titers in 100% of tested animals, with a geometric mean HAI titer of 1:130 against the A/Anhui/1/13 strain of H7N9 virus. This newly reported generation of strong T-cell immune responses tested by the ELISpot assay as well as the superb challenge data further demonstrates the power and potential of Inovio's universal flu vaccine franchise.

Using Inovio's synthetic consensus design approach the company has created universal DNA constructs for key virus clades (branches) within the Type A subtypes H1N1, H2N2, H3N2, and H5N1 as well as Type B. These constructs target multiple influenza antigens associated with influenza, including the most frequently changing antigen, HA. Inovio can mix and match these individual DNA plasmid constructs as desired to create vaccine candidates. Inovio has previously reported human data indicating protective immune responses against the subtypes H1N1 and H5N1.

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its synthetic consensus design approach is intended to help the immune system identify and fight cancer cells or multiple unmatched strains of a mutating virus. These proprietary synthetic vaccines, in combination with Inovio's electroporation delivery, have in humans generated best-in-class immune responses with a favorable safety profile. Inovio's lead vaccine, a therapeutic against HPV-caused diseases, is in phase II. Other phase I and preclinical programs focus on HIV, influenza, malaria and hepatitis C virus. Partners and collaborators include the University of Pennsylvania, VGX International, Merck, National Cancer Institute, U.S. Military HIV Research Program, NIH/NIAID, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security, University of Manitoba and PATH Malaria Vaccine Initiative. More information is available at http://www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2012, our Form 10-Q for the quarter ended March 31, 2013, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

(Logo: http://photos.prnewswire.com/prnh/20120131/LA44118LOGO)

Read the original:
Inovio Pharmaceuticals' Universal H7N9 DNA Vaccine Protects 100% of Vaccinated Animals in Challenge Study